Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: Relation of the in vitro chemosensitive test to clinical response
Autore:
Higashiyama, M; Kodama, K; Yokouchi, H; Takami, K; Nakagawa, H; Imamura, F; Minamigawa, K; Kobayashi, H;
Indirizzi:
Osaka Med Ctr Canc & Cardvasc Dis, Dept Thorac Surg, Higashinari Ku, Osaka5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis Osaka Japan 5378511 saka5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis, Dept Neurosurg, Osaka 5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis Osaka Japan 5378511 aka 5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis, Dept Resp Med, Osaka 5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis Osaka Japan 5378511 aka 5378511, Japan Nitta Gelatin Inc, Res Lab Div, Osaka, Japan Nitta Gelatin Inc Osaka Japan ta Gelatin Inc, Res Lab Div, Osaka, Japan
Titolo Testata:
ONCOLOGY REPORTS
fascicolo: 2, volume: 8, anno: 2001,
pagine: 279 - 283
SICI:
1021-335X(200103/04)8:2<279:CCFPRI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDIVIDUALIZED CHEMOTHERAPY; IMAGE-ANALYSIS; HUMAN TUMORS; EXPRESSION; RESISTANCE; CHEMORESISTANCE; CARCINOMA; SURVIVAL; CULTURE; ASSAY;
Keywords:
non-small cell lung cancer; chemosensitivity; collagen gel droplet embedded culture drug sensitivity test; in vitro chemosensitivity test; cisplatin; carboplatin; clinical response; recurrence;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Higashiyama, M Osaka Med Ctr Canc & Cardvasc Dis, Dept Thorac Surg, Higashinari Ku, Nakamichi 1-3-3, Osaka 5378511, Japan Osaka Med Ctr Canc & Cardvasc Dis Nakamichi 1-3-3 Osaka Japan 5378511
Citazione:
M. Higashiyama et al., "Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: Relation of the in vitro chemosensitive test to clinical response", ONCOL REP, 8(2), 2001, pp. 279-283

Abstract

The usefulness of the in vitro chemosensitivity test, the collagen gel droplet embedded culture drug-sensitivity test (CD-DST, Int J Oncol 11: 449, 1997), in cisplatin-based combined chemotherapy for postoperative recurrent tumors in non-small cell lung cancer (NSCLC) patients was retrospectively analyzed. CD-DST data for cisplatin (or carboplatin), etoposide, 5-fluorouracil, mitomycin C, and vindesine were obtained in 311 surgically resected primary lesions. Of them, 25 patients were practically treated with first-line cisplatin- or carboplatin-based chemotherapy for postoperative initial recurrence. Nine (36%) of them responded to the combined chemotherapy for recurrent lesions, including one with complete remission, whereas 16 did not, with no change in 5 and progression in 11. Seven (70%) of 10 patients receiving combined chemotherapy using two or three in vitro sensitive chemoagents showed good responses, whereas there was no responder among the patients receiving chemotherapy including no in vitro sensitive chemoagents. In particular, of 11 patients showing good sensitivity to cisplatin or carboplatinon CD-DST, 8 (73%) responded to chemotherapy, whereas only one (7%) of 14 patients showing cisplatin- or carboplatin-resistance on CD-DST was a responder. Thus, CD-DST results for the chemoagents, especially cisplatin or carboplatin, correlated with chemotherapeutic response, indicating that the CD-DST analysis of surgically resected primary NSCLC tumors is a practically useful indicator of the clinical effect of first-line cisplatin-based combined chemotherapy for postoperative recurrence.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 01:56:52